stockportfolio.pro
Catalyst Pharmaceuticals, Inc. (CPRX)
Healthcare · Biotechnology · NasdaqCM
Catalyst Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $500,000 | $102.31M | $119.07M | $140.83M | $214.20M | $398.20M | $491.73M | $588.99M |
| Gross profit | — | — | — | $87.55M | $102.03M | $118.95M | $179.81M | $346.24M | $422.89M | $501.74M |
| Net income | $-18.07M | $-18.41M | $-34.00M | $31.88M | $74.98M | $39.48M | $83.08M | $71.41M | $163.89M | $214.33M |
| Net margin | — | — | -6800.7% | 31.2% | 63.0% | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
Source: Catalyst Pharmaceuticals, Inc. SEC filings (10-K). 24 years of history available in the interactive view.
Explore 24 years of Catalyst Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CPRX in your portfolio →
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals, Inc. — frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s revenue?
Catalyst Pharmaceuticals, Inc. (CPRX) reported revenue of $588.99M for fiscal year 2025, up 19.8% from the prior year, according to its SEC filings.
Is Catalyst Pharmaceuticals, Inc. profitable?
Yes. CPRX earned net income of $214.33M in fiscal 2025, a net margin of 36.4%.
What is CPRX's P/E ratio?
Catalyst Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 18.1 based on the latest data in our nightly-refreshed cache.
How fast is Catalyst Pharmaceuticals, Inc. growing?
CPRX's revenue grew at roughly 37.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Catalyst Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 24 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.